ArticleNew microbes and new infections2026
The epidemiology of
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the epidemiological characteristics of Methods: A total of 12504 patients with respiratory diseases were included, and age, gender, and month were analyzed for their association with MP infection. The effect of COVID-19 prevention and control was evaluated by comparing positive rates from 2018 to 2023. Results: In 2023, the MP-positivity rate peaked in October at 59.18% (390/659) and was predominantly seen in pediatric patients. In addition, comparison with previous years revealed a higher infection rate in children aged 0-3 years in 2023. A significant difference was observed in positive rates before, during, and after COVID-19 prevention and control, with the highest rate post-control; and females had a higher infection rate in all three periods. In a word, the 2023 MP-positive rates surge, the marked increase in susceptibility among children aged 0-3, and the consistently higher infection rate in females. Conclusion: The study suggests a significant increase in MP positive rates, particularly in pediatric patients and females in 2023. The implementation of COVID-19 prevention and control measures may have contributed to the higher infection rate observed after its removal. In conclusion, the 2023 MP epidemic represents a significant shift in post-pandemic infectious disease dynamics. Understanding this surge may require a comprehensive view within a Multifactorial Framework which contain Natural Epidemic Cycle, The "Immunity Debt" Hypothesis and Behavioral and Ecological Factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.